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Objectives: Measuring the amount of progestin remaining in contraceptive implants used for different lengths of time provides useful information on
in vivo release kinetics including change over time.We compared estimated in vivo levonorgestrel (LNG) release rates derived from Sino-implant (II)
explants with similar data from removed Jadelle.
Study design: We measured LNG remaining in 44 sets of Sino-implant (II) used for up to 7 years and removed in four Chinese clinics. Results
were comparedwith published data for Jadelle explants used for up to 36months.We estimated and comparedmonthly and daily LNG release rates
for the two products using prediction models for drug release. We also estimated the dissolution profile similarity factor, f2, for LNG release.
Results: Both Sino-implant (II) and Jadelle release approximately 30% of total LNG load after 3 years. Results of fitting the data to a biologically
plausible modified Higuchi prediction model indicate comparable release through 3 years. An estimated similarity factor of 80.6 (90% confidence
interval: 70.8–85.7) indicates similarity in the dissolution profiles of the two implants.
Conclusions: LNG release in vivomeasured through explant analysis suggest that Sino-implant (II) and Jadellemay perform similarly through 3 years
of use and could remain highly effective beyond this time point. These results align with published data for Jadelle and Sino-implant (II) showing high
effectiveness for 5 years. Ongoing clinical studies comparing the products over 5 years present an opportunity to verify this supportive measure of
clinical effectiveness.
Implications: This innovative approach provides evidence that Sino-implant (II) may perform clinically similarly to Jadelle over 3 years and
remain a highly effective contraceptive beyond this time point. Data from explant analyses show promise for investigating the equivalence of
elusion profiles of contraceptive implants.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).Keywords: Sino-implant (II); Contraceptive implant; Explant; Jadelle; China1. Introduction
The subdermal contraceptive implant Sino-implant (II)
has been used by more than seven million women since its
introduction in 1996 and is currently registered for use inmore than
25 countries. Just like the implant system Jadelle, Sino-implant (II)
consists of two Silastic® rods each containing 75 mg of☆ Funding: This study was funded by a grant from the Bill & Melinda
Gates Foundation.
☆☆ Conflicts of interest: The authors declare no conflicts of interest.
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http://dx.doi.org/10.1016/j.contraception.2015.06.028
0010-7824/© 2015 The Authors. Published by Elsevier Inc. This is an open access alevonorgestrel (LNG) (150 mg total). Four randomized trials
conducted in China with more than 15,000 women assigned to
Sino-implant (II) had first-year probabilities of pregnancy of
nearly 0%. Cumulative probabilities of pregnancy during the 4
years of the product’s approved duration of use were 0.9% and
1.06% in the two trials that presented data for 4-year use [1].
These annual pregnancy rates place Sino-implant (II) in the
category of “highly effective contraceptive methods” with
annual pregnancy rates between 0.0% and 0.9% per World
Health Organization (WHO) definition [2] along with other
implants, intrauterine devices and sterilization. While these
effectiveness data are compelling, they are not sufficient for
stringent regulatory approval of Sino-implant (II) primarily
because the clinical trials from which they come wererticle under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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were defined [3].
Currently, two GCP-compliant clinical studies in the
Dominican Republic and China are under way to support an
application forWHO prequalification of Sino-implant (II). While
this regulatory path does not involve making the claim that
Sino-implant (II) is a generic of the innovator product Jadelle,
evaluating the similarity of the two products is a goal of the
research since Jadelle is known to be a highly effective method.
FHI 360 has pursued two alternative approaches for
assessing the similarity of Sino-implant (II) and Jadelle. First,
in the ongoing clinical trials in the Dominican Republic and
China, the clinical performance of Sino-implant (II), along with
measures of total LNGconcentrations and sex-hormone binding
globulin, will be compared to Jadelle over 5 years of use.
Second, we have evaluated the release rate of LNG in vivo from
Sino-implant (II) and used appropriate statistical techniques to
compare the rate to that of Jadelle [4]. Initial results of the latter
approach are presented here.2. Materials and methods
2.1. Sample
Sino-implant (II) explants were obtained from an
evaluation of implant removal techniques at four Chinese
clinics in 2008 [5]. Use duration was determined using clinic
records and self-reported length of use in months document-
ed at the time of removal. The explants were stored in sealed
plastic bags at room temperature and tested at SGS
Laboratories, a Swiss-based global service organization
specializing in product inspection, testing, certification and
verification in Shanghai, China. In early 2010, 44 sets of
explant rods from this sample that had been used for 1 to 84
months were selected for analysis. Explants were selected
from three clients (two rods from the same client) who had
used the implants for the following lengths of time: 1, 6, 12,
18, 24, 36, 42/43, 48, 55, 60, 71/72 and 84 months, resulting
in a total of 36 explant sets. Eight additional sets of implants
that had been used to evaluate an LNG content assay
developed for lot release testing of Sino-implant were added
to the data set to increase statistical power. The explants were
rinsed following a contraceptive implant decontamination
procedure developed by the University of North Carolina
Infectious Disease Laboratory involving submerging the
explants in a 10% chlorine bleach/water solution for 10 min
at room temperature, rinsing the explants in distilled water
and drying at room temperature. The cleaning protocol had
previously been shown to not affect the accuracy and precision
of the LNG assay.
2.2. Measurement of LNG
Procedures for testing single explants for LNG content
were based on a publically available analysis standard
approved by the China State Pharmacopoeia Commissionand originally developed for lot release testing of new
implants [6]. FHI 360 previously validated this method for
newly manufactured implants as part of the WHO prequal-
ification process and subsequently validated it for explants.
In brief, explants were cut into small fragments (~1-mm
lengths), submerged in 10 mL of chloroform (reagent grade;
TEDIA Company) for at least 3 h and then diluted with
ethanol (absolute; Sinopharm Chemical Reagent Co.) to a
100-mL volume. Two sequential dilutions with ethanol
(each with diluting 5 mL of the previous solution to 50 mL)
were conducted to yield a final theoretical concentration
of 0.0075 mg/mL LNG based on a 75-mg/rod initial level
of LNG before insertion. With UV spectroscopy (UV-
Shimadzu-2450PC), absorbance was determined at 240 nm
(1-cm path length using a quartz cuvette) from the average
of three replicate spectra. LNG content of the sample was
calculated based on the absorbance of a LNG standard
(National Institute for Food and Drug Control in China)
determined under the same conditions. An LNG standard
curve was prepared with eight standard concentrations
ranging from 0.0008 to 0.0090 mg/mL of LNG in ethanol,
containing 0.1% (v/v) chloroform. Accuracy was consid-
ered compliant if recovery for each sample was found to be
within 98%–102%. Precision was considered compliant if
the percent relative standard deviation (% RSD) for each
solution is less than 2. For LNG levels ranging from 10%
(0.0008 mg/mL) to 120% (0.009 mg/mL) of the label claim,
the accuracy of the test method was found to be within
98.4%–101.5% recovery, while the precision ranged from
0.1% to 2.0% RSD. The average of the LNG content
measurement at each time point was calculated for single
rod explants.
We compared mean release rates for the observed
Sino-implant (II) data over 3 years of use to publicly
available data for 263 Jadelle explants which are reported in
100-day intervals over 3 years using the manufacturer’s
proprietary assay not in the public domain [7,8]. We then
used the data for Sino-implant (II) to calculate release curves
over the same period as that reported for Jadelle.
2.3. Statistical analysis
We considered two models for predicting mean LNG
release over time:
loss ¼ α daysð Þ0:45
and
loss ¼ αþ β1 daysð Þ0:5 þ β2  days:
The first is a biologically plausible, modified Higuchi
model [9] with zero intercept (i.e., 0% release at day zero)
where the exponent of days (0.45) is determined based on the
geometry of diffusion from a cylinder [10]. The second
model was previously used by investigators at the Population
Council when summarizing performance of Jadelle [8] and
Table 1
Cumulative mean and percent LNG released per set of explants.
Jadelle Sino-implant (II)
Days of use N Mean mg (SD) % Released N Mean mg (SD) % Released
1–100 20 8.7 (6.7) 5.8 4 9.1 (2.1) 6.0
101–200 32 14.0 (8.8) 9.3 3 18.3 (7.0) 12.2
201–300 35 20.3 (5.1) 13.5 1 17.0 (NA) 11.3
301–400 25 22.6 (9.4) 15.1 4 25.0 (2.4) 16.6
401–500 22 27.2 (6.3) 18.8 – – –
501–600 29 30.6 (5.7) 20.4 4 30.8 (3.3) 20.5
601–700 32 32.7 (7.3) 21.8 – – –
701–800 26 32.9 (5.1) 21.9 4 36.8 (5.4) 24.5
801–900 16 43.3 (4.4) 28.9 – – –
901–1000 16 43.7 (3.7) 29.1 – – –
1001–1100 5 48.6 (3.6) 32.4 4 43.2 (3.5) 28.8
1101–1200 5 49.7 (4.2) 33.1 – – –
1201–1300 – – – 2 45.4 (1.0) 30.3
1401–1500 – – – 3 48.5 (11.4) 32.3
1601–1700 – – – 4 51.1 (2.7) 34.1
1801–1900 – – – 5 57.7 (7.0) 38.0
2101–2200 – – – 3 60.5 (4.2) 40.3
2501–2600 – – – 3 74.7 (0.7) 49.8
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intercept and a nonzero asymptotic LNG release rate. We
fit each model using weighted least squares applied to
interval midpoints on data collected through day 1100 (the
overlapping range of available data for the two implants).
We also estimated the release of LNG per day by taking
the derivative of the release functions with respect to time,
as follows:
dl
dt
¼ 0:45  α daysð Þ−0:55
and
dl
dt
¼ 0:5β1 daysð Þ−0:5 þ β2;
where β2 corresponds to the asymptotic release rate of LNG
under the model previously used by the Population Council.
In addition, we compared the rates of LNG release over
time by estimating the similarity factor, f2, a value commonly
used to compare two dissolution profiles [4,11].
This factor is estimated as
f^ 2 ¼ 50  log10 1þ 1=pð Þ
Xp
i¼1
xti−xrið Þ2
" #−12
 100
8<
:
9=
;;
where xti and xri are the average percent release values at
time point i for the test [i.e., Sino-implant (II]) and reference
(i.e., Jadelle) products, respectively, and p is the number of
time points selected. The statistic takes the value 100 if there
is perfect agreement between test and reference, with a lower
limit of 0. Although subjective, values of f2 between 50
(corresponding to an average difference of 10% in percent
release across time) and 100 (perfect agreement in releaseprofiles) indicate similarity between two dissolution profiles,
which provides evidence to support the possible bioequiv-
alence of the two products [11]. Though the f2 factor is not
used as a substitute for a bioequivalence study for a new
product, it is reasonable to use the measure to compare ex vivo
release profiles with extended-release products. For the
explant data described here, the estimation of f2 was restricted
to the six intervals of timewhere at least two observationswere
available for each implant method (days 1–100, 101–200,
301–400, 501–600, 701–800 and 1001–1100).3. Results
The mean LNG release data for Jadelle and Sino-implant
(II) at 100-day use intervals suggest comparable release
through 3 years (Table 1). Between 701 and 800 days, or
about 2 years, Sino-implant (II) and Jadelle had released
approximately 24.5% and 21.9% of the LNG, respectively.
After 7 years of use, half of the LNG remained in the
Sino-implant (II) samples. The release curves are compara-
ble for Sino-implant (II) and Jadelle implants through year 3
based on the modified Higuchi model (Fig. 1a), with an
estimated 42.9 mg of LNG (28.6% of the initial load) lost by
year 3 among Sino-implant (II) users [95% confidence
interval (CI): 41.2–44.5 mg] and 41.9 mg (27.9% of the
initial load) for Jadelle users (95% CI: 39.4–44.3 mg). There
was greater apparent discrepancy in predicted release curves
between implant types when fitting the Population Council
model (Fig. 1b), although the cumulative release through
year 3 was not statistically significant between implant types:
44.1 mg released (95%CI: 41.5–48.6 mg) among Sino-implant
(II) users and 47.6 mg released (95% CI: 43.6–51.5) among
Jadelle users (p = .161). We also estimated a similarity
factor (f2) of 80.6 (90% CI: 70.8–85.7), indicative of
a)
b)
Fig. 1. (a) LNG released over 3 years estimated using amodifiedHiguchimodel. (S-I (II):Q = 1.838*days0.45; Jadelle:Q = 1.796*days0.45). (b) LNG released over 3
years estimated using the Population Council model. (S-I (II): Q = 0.412 + 1.29*days0.5 + 0.00094*days; Jadelle: Q = 3.509 + 0.647*days0.5 + 0.0207*days).
353R.L. Callahan et al. / Contraception 92 (2015) 350–355substantial agreement between the percent release profiles of
the two products.
For predicted daily LNG release rates, the modified Higuchi
model (Fig. 2a) shows substantial agreement between Sino-
implant (II) and Jadelle. Estimated daily release rates at year 2
are 22.0 mcg/day (95% CI: 21.2–22.9) and 21.5 mcg/day (95%
CI: 20.2–22.8), respectively, for Sino-implant (II) and Jadelle
users, while at year 3, the corresponding rates are 17.6 mcg/day
(95% CI: 16.9–18.3) and 17.2 mcg/day (95% CI: 16.2–18.2).
Results of fitting the PopulationCouncilmodel (Fig. 2b) suggest
higher daily release rates for Jadelle than Sino-implant (II) at
year 2 (32.6mcg/day versus 24.8mcg/day; p = .084) and year 3
(30.4 ng/day versus 20.4 ng/day; p = .110), but the differences
were not statistically significant. The release rates for bothproducts appear to level off and remain relatively stable between
year 1 and year 3, regardless of model fit to the data. Given the
relative “flatness” of the curves and previously established
release kinetics for Jadelle showing steady release through 5
years [12], it is not unreasonable to assume that the trend would
continue for Sino-implant (II).4. Discussion
The results of this explant analysis indicate that
Sino-implant (II) and Jadelle release LNG at similar rates
through 3 years of use and, therefore, should have similar
contraceptive effectiveness over this period. The modified
a)
b)
Fig. 2. (a) Predicted daily release rates of LNG using a modified Higuchi model. (S-I (II): dQ/dt = 0.45*1838/days0.55; Jadelle: dQ/dt = 0.45*1796/days0.55).
(b) Predicted daily release rates of LNG using the Population Council model. (S-I (II): dQ/dt = 0.5*1290/days0.5 + 0.94; Jadelle: dQ/dt = 0.5*647/days0.5 + 20.7).
354 R.L. Callahan et al. / Contraception 92 (2015) 350–355Higuchi and the Population Council models for estimating
LNG release produce comparable results through 2 years.
Although the two models diverge somewhat in year 3 with
the Population Council model predicting somewhat
higher release rates for Jadelle, we believe the assumptions
inherent to the modified Higuchi model to be more
biologically plausible. The relatively high (80.6) similarity
factor, f2, aligns with the model results indicating similar
in vivo release of the two products. In addition to
quantitatively describing the similarity of the two dissolution
curves, the f2 is sensitive to large differences in any
particular time point [11].
The results of this analysis support findings from clinical
trials in China [1] as well as more recent study resultsindicating that Sino-implant (II) performs as well as Jadelle
in the first year of use. Surveillance studies in Bangladesh,
Kenya, Pakistan and Madagascar involving more than 2500
women showed first-year pregnancy rates from 0.0% to
0.4% among users of Sino-implant (II) [13–15].
While our findings are reassuring, they should be viewed
with caution given several limitations of the analysis. First,
we measured LNG release from Sino-implant (II) using a
validated assay for the particular product and compared the
results to published data for Jadelle. Although we assume
that the assay method used with the Jadelle explants was
validated for the product, a description of the methods used
in the Jadelle analysis is not publically available. We,
therefore, cannot rule out possible measurement bias
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studies. Similarly, the explant data for Sino-implant (II) and
Jadelle come from different populations of users, and
although we assume that in situ release would not vary by
ethnic group or other physical characteristics of the users, such
differences could affect results. The analysis is also limited by
the relative sparseness of the Sino-implant (II) data and the fact
that we had to group the data into 100-day intervals tomatch the
available Jadelle results. We compared data from 24 Sino-im-
plant (II) explantswith removal times self-reported bymonths of
use over a period of 3 years to those of 263 Jadelle explants.
While the Sino-implant (II) data were sufficient for estimating
the f2 similarity factor, our results would be more robust with
additional data points. Finally, the predicted release rates are
highly dependent (both in absolute and in relative terms) on
which model is fit to the data. While the modified Higuchi and
PopulationCouncil models produce reasonable results that align
with the available observed data, whether or not these are the
most appropriate models for release rate data from subdermal
implants is currently uncertain. Although our analysis does not
meet the full set of guidelines for comparison of in vitro
dissolution profiles as described by the European Medicines
Agency [4], the results provide evidence of similarity between
the two implant systems.
The ongoing 5-year effectiveness study of Sino-implant (II)
in the Dominican Republic, which includes 650 women
randomized in a 4:1 ratio to either Sino-implant (II) or Jadelle,
provides the opportunity to confirm the present study results
where the methods are used by the same population over longer
use durations. In addition, LNG levels remaining in the explants
will be compared to plasma LNG concentrations, which are
collected at 6-month intervals and at the time of removal.
Our assessment of in vivo release of LNG from Sino-implant
(II) represents an innovative supportive measure for evaluating
the similarity of contraceptive effectiveness of long-acting
contraceptive methods. After further validation work of this
approach, regulatory bodies and WHO’s prequalification
program could establish guidelines for extended-release methods
that include comparative data from explant analyses. Such
guidelines could apply in the review of Sino-implant (II) as well
as future long-acting contraceptives (or other pharmaceuticals).
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